That is necessary, because the method a protein in the human body folds identifies if a pharmaceutical will have the ability to bind to that protein and be efficient. In other words, we need to understand how these proteins fold if we desire a drug to work. Historically, this has actually been an experimental process (korean actress). Now, Alpha, Fold can predict protein folding with 92. 4% precision. That's going to make it much easier to develop drugs that do what they're created to do. This was an advancement nearly nobody observed. However it's going to have extensive ramifications for curing illness. I predict that Alpha, Fold will be 98% accurate by the end of 2021.
And, of course, there will be lots of financial investment opportunities in this space, too. Shifting topics It's going to be a great year for bitcoin. I'm bullish on it in 2021 (future report review). That stated, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be amazed if it pulled back perhaps considerably before going greater - melania trump. I've been covering bitcoin for a long time now. Among the very first research reports I ever released was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that initial recommendation, I titled my report "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time. We were mainly educating readers. However that's not the huge concern any longer. Now we're seeing institutional money lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche business. Mass, Mutual is a trusted 170-year-old institution. So think of that. In 5 years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a huge factor I'm bullish on it this year. last week. Regards, Jeff Brown, Editor, The Bleeding Edge I have a benefit forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I forecast 2021 will be another record year in IPOs. There are a lot of fantastic personal business on the edge of striking the public markets And I've been working on a new way for you to invest even before these business go public.
This chance has actually been building over the last few years. I can't wait to tell you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to learn all the information. Go right here to reserve your spot free of charge.
Emma Walsh here, handling editor of the Journal. Regular Diary readers know that tech isn't our usual beat (genetic sequencer stock jeff brown). And when it pertains to tech investing, we leave it to the specialists. Thankfully, we have a number of such specialists in our Rolodex. Our associate Jeff Brown will recognize to our longtime readers. He is among the most accomplished tech investing professionals we understand (jeff brown biotech pick). In fact, he had numerous triple-digit returns in his Brownstone Research portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take a look at the big image and predict what's simply around the corner.
That includes things like 5G networks, biotech, synthetic intelligence, and a lot more. These patterns are experiencing rapid development and producing incredible chances for investors. I want to make sure all our readers are gotten ready for what's next. And with that in mind, let me draw the image of what I see coming in the next 12 months Our brand-new 5G (fifth-generation) wireless networks are a subject I've been covering for years now. united arab emirates. But in spite of what lots of readers might think, this is a trend that's simply beginning. Even though the COVID-19 pandemic interrupted supply chains last year, an excellent 250 million 5G-enabled gadgets were still offered.
And all of this eventually resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by two months (jeff brown stock predictions). Losing 2 months of production and sales actually impacts the number of 5G devices are sold in the fiscal year. When you think about all of that, offering 250 million units is amazing. More importantly, the hold-ups triggered by the pandemic created a lots of pent-up demand. And that need is now going to be pressed into 2021. In reality, I forecast that more than 500 million 5G gadgets will be shipped in 2021 - exponential growth. And that's not my only 5G forecast When I have actually discussed 5G in the past, I have actually described its 3 different phases.
In Phase 2, 5G gadgets go on sale. 5G phones and other items begin to reach customers. And in Stage Three, 5G services begin to be used (biotech stock). That's when we begin to see applications running on 5G networks. Think of things like enormous multiplayer video games over a smart phone. That's not possible with 4G. It will be with 5G. And my 2nd 5G forecast for 2021 is that we will begin Stage Three by this summertime. This starts something of a virtuous cycle: The majority of people don't actually appreciate the innovation. But they will care if there are interesting applications that can only be accessed with a 5G phone.
That causes more 5G apps being developed. In truth, 5G is going to open up a suite of incredible applications: self-driving vehicles, the Internet of Things, robotic surgical treatment, and more. All of these technologies need 5G. The financial investment opportunities moving forward will be huge. Stepping away from 5G, the next important technology I anticipate in 2021 is CRISPR hereditary editing. CRISPR represents "clustered frequently interspaced brief palindromic repeat." It's a mouthful. But it is among the most interesting developments in biotechnology. At a high level, CRISPR is an innovation that can edit our hereditary makeup as if it were software.
The program can crash or not function correctly. CRISPR uses a comparable idea however with our genetic code. "Typos" in our genome can cause disease. CRISPR can remedy these "typos." For many years, CRISPR was primarily a specific niche technology that wasn't well comprehended. And throughout that time, there were actually just three companies running in this area. However things are altering. CRISPR is no longer just theoretical. We're seeing actual results. We're treating diseases and seeing that this innovation simply works. And as a result, a "second crop" of early-stage CRISPR companies is going public and providing unbelievable returns. This whole industry is efficiently a greenfield opportunity.
There's space for lots of companies to exist in this space. artificial intelligence. And there will be more. That's my prediction for CRISPR in 2021. I predict that 2 or 3 more hereditary editing companies will hold their IPOs. Sticking with biotechnology, we are seeing incredible things happening at the convergence of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, just announced at the end of 2020 that its newest Alpha, Fold software application can accurately predict the folding of a protein based solely on its amino acid series with 92. 4% accuracy. That is essential because the method a protein in the human body folds determines if a pharmaceutical will be able to bind to that protein and work.
Historically, this has been an experimental procedure. Now, Alpha, Fold can predict protein folding with 92. 4% precision. That's going to make it much easier to develop drugs that do what they're designed to do. And here's my next prediction. I anticipate that Alpha, Fold will be 98% precise by the end of 2021. And we will see not simply one however a number of drug therapies produced utilizing this technology. This was among those breakthroughs that almost no one observed. But it's going to have extensive implications for treating illness. And, naturally, there will be plenty of investment opportunities in this area, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That stated, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I would not be surprised if it drew back maybe substantially before going higher. I have actually been covering bitcoin for a very long time now. Among the first research reports I ever published was on bitcoin - united states. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for anybody who followed my suggestion. However at the time of that preliminary suggestion, I titled my report, "What's the Big Offer With Bitcoin?" That reveals you where the conversation was at the time.
But no one is asking that question any longer. Now, we're seeing institutional money finally taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, specific niche business. last week. Mass, Mutual is a 150-year-old organization. So consider that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a big reason that I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more bonus forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and claims the information depends on date since February 2021, but we might not independently validate this claim. Offered Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down an accurate figure at this minute. Brown is best understood for his sage-like capability to choose winning innovation stocks. He spent more than 25 years researching innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's comprehensive experience provides him an outstanding perspective on the marketplace. He's constantly on the hunt for new opportunities, and he shares a number of his best picks in the Near Future Report.
That's high praise, but it's not absurdly reasoned. Brown has an excellent track record as a stock-picker, and he successfully anticipated a few of the greatest economic occasions of the past 20 years. Although he doesn't appear to launch his picks to the public, the service's success is a direct indicator of Brown's stock-picking expertise. Nobody on Wall Street gets it ideal every time, but Jeff Brown's precise forecasts have actually earned him legions of devoted fans. That states a lot about his capability. The Near Future Report is published by Brownstone Research study, a prominent monetary research study publisher. Brownstone Research uses several research services with a variety of specializations - future report.
The company is also affiliated with Bonner & Partners, another well-respected research study publisher - toxic tech 5 tech darlings. On its website, Brownstone states its mission is to supply retail investors with professional-grade research study: "For too long, the finest investment research study has not been available to individual investors. It has been typically reserved for investment banks, hedge funds, private equity, and high-net-worth customers. future report. The mission of Brownstone Research study is to make that kind of exclusive research study offered to any investors looking to acquire an edge in the markets. The objective is basic to deliver unique and successful investment research study discovered no place else." -Brownstone Research website excerpt from the Jeff Brown is the founder of Brownstone Research, and he likewise functions as the firm's Chief Financial investment Expert.
With Brown guiding the ship, Brownstone Research study is a powerhouse publisher with lots to use its customers. After decades of stable success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a home name throughout the majority of America. If you know even a little bit about the market, you understand that he has a track record as a King Midas of sorts. jeff brown investor prediction. Everything he touches turns to gold! Jeff is aware of Elon Musk's executive prowess, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge job.
In fact, Brown thinks S.A.V. biotech stocks. could be "the biggest pattern of the 2020s, and he's not alone. Take a look at these quotes from other widely known S.A.V. bulls: Elon's next big act will be weding two innovative innovations: expert system and electrical cars and trucks. Musk hopes the combination will assist him develop the very first fully-autonomous, self-driving vehicles ever. It's nothing except the vehicle industry's Holy Grail. As you understand, electrical automobiles and self-driving automobile stocks have actually been big this year, however the Wall Street maker has actually approved buzz without much tangible outcome. Regardless of an extreme boost in competition over the previous couple of years, Brown still thinks Musk has the best possibility of putting all of it together.
tech might be the magic string that ties it all together. S.A.V. means Shared Autonomous Lorry, and it might be the future of transportation. Basically, this innovation would enable you to rent your automobile as an autonomous, self-driving taxi when you're not using it. You just get out of the automobile and press a button on an app that tells the vehicle to "join the fleet." Next thing you understand, you're relaxing on your couch while your car shuttles ride-sharers around town. Most importantly, you get to keep a large piece of the revenues. It sounds insane, but it could be closed than you believe.